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Abstract 
Background: Untreated tricuspid regurgitation during mitral valve surgery may 
progress to severe symptomatic tricuspid regurgitation. Concomitant repair may 
increase the operative risk; however, re-operative tricuspid valve surgery is a high-
risk procedure. This study's objective was to identify the predictors of DeVega repair 
failure in patients with functional tricuspid regurgitation and concomitant mitral 
valve surgery.  
Methods: This research is a retrospective comparative study that included 140 
patients who underwent tricuspid valve repair concomitant with mitral valve 
replacement. We divided the patients into two groups; the first group (n=106) 
included patients with no DeVega failure at six-months follow-up (The sustained 
repair group). The second group included 34 patients who developed moderate or 
higher TR after the DeVega and was named the failed repair group. 
Results: The demographic data and comorbidities were not statistically different 
between both groups. The preoperative atrial fibrillation (73 (69%) vs. 30 (88%)’ p= 
0.027) pulmonary artery pressure (64.8±3.6 vs. 81±6.5 mmHg; p= 0.02), right 
ventricular dimension (4.85±0.24 vs. 5.23±0.37 cm; p= 0.03), and time between the 
indication of surgery and operation (8.3 ± 3.1 vs. 14.7 ± 5.4 months; p = 0.003) were 
higher in patients with failed DeVega repair. There was no statistically significant 
difference regarding the mean bypass time, cross-clamp time, ICU and hospital stay, 
and postoperative complications between both groups. Predictors of failure after six 
months were preoperative heart failure (OR: 15.4 (95% CI: 3- 92.3); p= 0.003), long 
time between diagnosis and surgery (OR: 12.3 (95% CI: 2.1- 84.7); p= 0.007), and 
postoperative severe pulmonary hypertension (OR: 24.7 (95% CI: 3.1- 199.6); p= 
0.003). 
Conclusions: DeVega repair is associated with a high failure rate after six months. 
The study of predictors of failure could change our management plans to reach the 
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Introduction 
Functional tricuspid regurgitation (FTR) usually 
occurs secondary to a left-side heart valve disease. 
FTR occurs in one out of three patients with 
rheumatic mitral stenosis [1]. Surgical correction 
of severe concomitant tricuspid regurgitation (TR) 
is recommended during left-sided valve surgery. 
However, the surgical treatment of mild to 
moderate FTR is still controversial. Some surgeons 
argue that FTR will regress spontaneously after 
treating the left side lesion [2]. On the other hand, 
several patients with untreated mild to moderate 
FTR returned because of the progression of their 
FTR to a severe degree [3]. Thus, it is unknown 
whether we should tackle mild to moderate FTR at 
the same sitting or be left to regress after 
correction of the mitral lesion. One can assume 
that if we repair every dilated tricuspid valve (TV) 
annulus, you will see less late TR on 
echocardiography. But, adding TV surgery could 
increase the risk of mitral valve surgery. 
Recurrent regurgitation after DeVega 
annuloplasty is not uncommon. However, 
reoperation is rare, although many patients are 
symptomatic with New York Heart Association 
(NYHA) class III or IV. This could be attributed to 
the perception of reoperation as a high-risk 
procedure. Patients present to re-operative 
tricuspid valve surgery are usually older, with bad 
preoperative status, and a higher probability of 
permanent pulmonary hypertension, right 
ventricular dysfunction, and hepatic impairment 
or failure [4].  
Our study aims to evaluate the outcomes of 
concomitant DeVega repair at the time of mitral 
valve operation in mild and moderate FTR and 
identify early failure predictors. 
Patients and Methods: 
This research is a retrospective comparative 
study that included 140 patients with mitral valve 
disease and FTR who underwent mitral valve 
replacement with concomitant DeVega repair 
from January 2017 to December 2018. We 
extracted their data from the paper charts and the 
computerized Cardiac surgery information registry 
system. We excluded patients with aortic valve 
lesions, coronary artery disease, re-do or 
emergency cases, and cases that underwent mitral 
repair. 
We divided the patients into two groups; the 
first group (n=106) included patients with no 
DeVega failure at six-months follow-up (The 
sustained repair group). The second group 
included 34 patients who developed moderate or 
higher TR after the DeVega and was named the 
failed repair group. 
Preoperative, operative and postoperative 
variables were extracted and recorded. We 
compared the need for pacemaker, liver or kidney 
dysfunction, dysrhythmia, prolonged need for 
inotropes, re-exploration, and bleeding between 
groups. We assessed the postoperative NYHA class 
and performed transthoracic echocardiography 
evaluation (TTE) before the operation, pre-
discharge, and six-month postoperative for all 
patients. The degree of TR, ejection fraction (EF), 
left ventricular end-diastolic dimension (LVEDD), 
the left atrial dimensions (LAD), systolic 
pulmonary artery pressure (SPAP), and right 
ventricular dimensions (RVD) were registered and 
compared.  
Surgical technique: 
All patients had surgery through conventional 
sternotomy. We initiated the cardiopulmonary 
bypass via aorto-bicaval cannulation. Myocardial 
protection was maintained with intermittent 
antegrade blood cardioplegic solution and topical 
cooling every 28-35 minutes interval. Surgical 
exposure of the mitral valve was achieved through 
left atriotomy incision in the Waterston groove. 
The mitral valve was replaced with a mechanical 
prosthesis with the preservation of the posterior 
leaflet in most cases.  
Tricuspid Annuloplasty (DeVega): 
After aortic de-clamping, an oblique right 
atriotomy was done after snaring the cavae. Then, 
the DeVega annuloplasty technique was used for 
tricuspid valve repair.  The posterior and the 
anterior parts of the annulus were plicated using 
3-0 polypropylene or 2-0 polyester double-armed 
with a purse-string suture. The bites were nearly 5 
82 
mm in length and 3 mm in depth, leaving 5 mm 
between bites. A second Teflon was passed onto 
the free ends of the suture. The suture was 
tightened down over a sizer of 27-29 mm and, 
after that, hardly admitting two fingers. We tested 
the repair to confirm that no residual regurgitation 
before closing the right atrium (Figure 1 and 2). 
and Trans-esophageal echocardiography (TEE) 
assessment was done by the anesthetist after 
coming off bypass.
Figure 1: Placement of the first raw of the suture 
through the tricuspid annulus 
Figure 2: Saline testing and ballooning of tricuspid 
valve leaflets after repair 
Statistical analysis: 
We used the IBM SPSS statistical software 
version 20.0 (IBM Inc., Armonk, NY, USA) to 
perform the final results. The used tests were 
unpaired student's "t" tests; for quantitative 
values and the chi-square (x2) test or Fisher exact 
test for qualitative values. Quantitative data were 
expressed as the means ± standard deviation, and 
qualitative data were expressed as numbers and 
proportions. The statistical difference was 
considered significant if the p-value was < 0.05. 
Results 
Preoperative data: 
The study group consisted of 140 patients. 
Patients' demographic and preoperative clinical 
data, NYHA class, and TR's degree were 
presented in Table 1, with no statistically 
significant difference between both groups. 
There were statistically significant differences 
between both groups regarding the 
preoperative rhythm and echocardiographic 
parameters (SPAP and the RV size) (Table 1). 
Operative and postoperative data: 
There was no statistically significant difference 
regarding the total bypass, cross-clamp times, 
operative complications, intensive care unit (ICU), 
hospital stay, and postoperative complications 
(Table 2). In the sustained repair group, 32 (30.2%) 
patients had trivial and mild TR, while in the failed 
repair group, 22 (64.7%) cases had mild TR, and 12 
(35.3%) cases had moderate TR. Although the 
difference in other echocardiographic data was 
non-significant, the mean SPAP was significantly 
higher in the second group (66.31 ± 3.4 versus 38.5 
± 6.4 mmHg; p-value = 0.013). 
The six-months follow-up: 
The six-months postoperative follow-up NYHA 
class and echo assessment of the degree of TR and 
other echo data were presented in Table 3. In the 
failed repair group, 88.2% of patients had severe 
TR, which accounts for 21.4% of the patients' total 
number. The echo parameters were not 
significantly different regards the LV function or 
dimensions. The SPAP was higher in the second 
group (49.03±2.8 mmHg) versus 30.8±1.3 mmHg 
for the first group with a p-value < 0.001. The RV 
dimensions were also significantly different, with 
a p-value of 0.02. Regarding the NYHA class, we 
found 35.3% of the failed repair group with NYHA 
classes III and IV, while only 11.3% of the sustained 
repair group in these classes with p-value < 0.001. 
Predictors of DeVega failure: 
We compared the preoperative, operative, 
and postoperative data to determine the factors 
related to DeVega repair's failure at the follow-up 
period. We have compared these values of the 
failed repair group to those with sustained repair. 
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Table 1: Preoperative data. Continuous variables were presented as mean and SD and categorical variables as number 
and percentages 
Preoperative Data Sustained repair group (N=106) 




Age (years) 43.1 ± 5.1 45.4 ± 6.71 0.847 
Female 58 (54.7%) 20 (58.8%) 0.064 
Body surface area (m2) 2.02 1.93 0.062 
Smoking 28 (26.4%) 10 (29.4%) 0.071 
Diabetes mellitus 32 (33.2%) 12 (35.3%) 0.416 
Preoperative AF 73 (68.9%) 30 (88.2%) 0.027 
Time between indication of surgery & 
operation (months) 8.3 ± 3.1 14.7 ± 5.4 0.003 
NYHA Class 
Class I 18 (17 %) 4 (11.7%) 
0.148 Class II 38 (35.8%) 10 (29.4%) Class III 40(37.7%) 14(41.1%) 
Class IV 10(9.4%) 6 (17.6%) 
TR Grade 
Mild to moderate 16(15.1%) 4(11.8%) 
0.72 Moderate  42(39.6%) 14(41.2%) 
Severe 48(45.3%) 16(47.1%) 
Echocardiographic parameters 
Ejection fraction (%) 64.3±4.7 66.2±3.6 0.15 
LAD (cm) 5.7±0.63 5.9±0.42 0.136 
LVEDD (cm) 5.6±0.72 5.3±0.43 0.581 
SPAP (mmHg) 64.8±3.6 81±6.5 0.02 
RVD (cm) 4.85±0.24 5.23±0.37 0.03 
AF: atrial fibrillation; LAD: left atrial dimensions; LVEDD: left ventricular end-diastolic diameter; NYHA: 
New York Heart Association; RVD: right ventricular diameter; SPAP: systolic pulmonary artery pressure; 
TR: tricuspid regurgitation 
Logistic regression analysis was used to 
identify the independent predictors of DeVega 
failure (Table 4). The predictors were the 
persistence of severe pulmonary hypertension 
after surgery, the presence of preoperative heart 
failure signs, and the prolonged time between the 
indication of surgery and the time of operation. 
Discussion 
The debate among cardiac surgeons continues 
in terms of indication, timing, and the 
recommended surgical technique for TV repair. 
Recent studies have demonstrated that 
uncorrected significant FTR can worsen early and 
late outcomes due to TR and right-sided heart 
failure progression [4]. Therefore, it is 
recommended to treat FTR at the time of left-
sided valve surgery. The reported progression rate 
of trivial or mild FTR after successful mitral valve 
operation to moderate to severe FTR 
varies between 7.7% and 33.7% [5]. Moderate 
tricuspid regurgitation occurred in 12 (8.6%) of 
our cohort early after surgery and moderate or 
severe in 34 (24.3%) after six months. Some 
cases had a recurrent regurgitation with 
worse functional status, while others 
developed higher grades than the preoperative 
status. 
Observational data suggest that more than 
85% of patients with tricuspid annuloplasty for 
FTR become free from moderate or severe 
insufficiency at their 10- year follow-up, compared 
with less than one-half of those patients who 
underwent isolated mitral valve surgery [5]. The 
2012 European Society of Cardiology/European 
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Table 2: Operative and postoperative data. Continuous variables were presented as mean and SD and categorical 
variables as number and percentages 
Variables Sustained repair group (N=106) 
Failed repair group 
(N=34) P-value 
Cross clamp time (min) 71.3 ± 6.2 68.20 ± 9.4 0.075 
Total bypass time (min) 89.3 ± 7.6 96.7 ± 8.5 0.07 
Mechanical ventilation time (hours) 17.5 ± 5.4 15.3 ± 3.1 0.062 
Total ICU stay time (hours) 50.3 ± 4.2 47.2 ± 6.4 0.674 
Rapid atrial fibrillation 46 (43.4%) 16 (47.1%) 0.054 
Transient Heart block 12 (11.3%) 4 (11.7%) 0.8 
Bleeding > 600ml 14 (13.2%) 4 (11.7%) 0.470 
Exploration 10 (9.4%) 2 (5.8%) 0.06 
Transient renal dysfunction  6 (5.66%) 2 (5.8%) 0.8 
Prolonged inotropic support 12 (11.3%) 6 (17.6%) 0.07 
(ESC/EACTS) and 2014 ACC/AHA guidelines 
strongly encourage the surgical correction of less 
than severe FTR if the tricuspid annular dilation is 
greater than 40 mm in patients undergoing left-
sided valve surgery [6,7]. Furthermore, Frater 
pointed out that TR is dynamic, and previously 
moderate or severe TR may appear only mild in 
the operative room, and repair is recommended if 
there are prior episodes of right heart failure [8]. 
At least 56% of patients with mitral stenosis 
and moderate tricuspid regurgitation are more 
likely to have NYHA class III or IV before 
mitral valve surgery [9]. There was no 
statistically significant difference regarding the 
preoperative NYHA classification between our 
groups. Choi and colleagues also reported 
the same results regarding NYHA 
classification in their study [10]. 
Table 3: Postoperative TR grade and other echo parameters at six months in both groups. Continuous variables were 
presented as mean and SD and categorical variables as number and percentages. 
Variables Sustained repair 
group (N=106) 
Failed repair group 
(N=34) P-value 
TR grade 
No or Trivial  3 (2.8%) 0 
< 0.001 Mild  103 (97.2%) 0 Moderate  0 4 (11.76%) 
Severe 0 30 (88.2%) 
Echocardiography 
Ejection fraction (%) 63.1±3.67 62.8±3.6 0.84 
LAD (cm) 5.1±0.51 5.3±0.42 0.87 
LVED (cm) 4.91±0.45 5.4±0.43 0.07 
SPAP (mmHg) 30.8±1.3 49.3±2.8 < 0.001 
RVD (cm) 4.05±0.15 4.71±1.23 0.02 
NYHA class 
class I 54 (50.9%) 10 (29.4 %) 
< 0.001 class II 40 (37.7%) 12 (35.3%) class III 10 (9.4%) 8 (23.5 %) 
class IV 2 (1.9%) 4 (11.8%) 
LAD: left atrial dimensions; LVEDD: left ventricular end-diastolic diameter; NYHA: New York Heart 





Table 4: Multivariable logistic regression for the predictors of DeVega failure 
OR P-value 
95% CI for OR 
Lower Upper 
Heart failure signs 15.365 0.003 2.559 92.261 
Preoperative AF 2.320 0.401 0.326 16.499 
Preoperative dilated RV 2.871 0.235 0.505 16.336 
Prolonged time between the indication of 
surgery and the time of operation 12.314 0.007 2.123 84.675 
Preoperative severe SPAP .673 0.717 0.079 5.753 
Postoperative severe SPAP 24.741 0.003 3.067 199.556 
The preoperative echocardiographic 
parameters in our study group revealed that the 
mean EF in the sustained repair group was 
64.3±4.7%, and 66.2±3.6% in the failed repair 
group. Others reported lower EF than our study 
[9]. The preserved function in our study may be 
explained by that rheumatic mitral stenosis 
protects left ventricular function, and our cohort 
does not include any patient with other cardiac 
diseases as ischemia or aortic valve pathology. The 
LVEDD and LAD were non-significant between 
both groups.  
The SPAP and the right ventricle dimensions 
were significantly different between both groups. 
The SPAP was higher in the failed repair group and 
was associated with more dilated RV than the 
sustained repair group. In contrast to Pradhan's 
group's study, their patients had PAP of 71.52 
mmHg for the DeVega group vs. 48.6 for the non-
repair group, and there was no statistical 
difference at the three-months follow-up in the 
SPAP or the degree of TR between the two groups 
[11]. Moreover, Nardi et al. reported SPAP of 60 ± 
22 mmHg preoperative vs. 32 ±10 mmHg 
postoperative, and despite this, they reported 
100% freedom of significant TR after one year [12]. 
This difference may be attributed to the primary 
pathology and other factors like the rheumatic 
mitral stenosis and the long time between 
diagnosis and surgery where the PAP and RV 
remodeling will be more affected. 
Choi's study showed a statistically significant 
difference regarding the cardiopulmonary bypass 
time [10]. In contrast, there was no statistically 
significant difference in our study regarding the 
cardiopulmonary bypass time or the cross-clamp 
time in both groups. This difference may be due to 
our preferred technique in performing TV 
annuloplasty after removing the cross-clamp. 
 In our study groups' early postoperative 
course, there was no statistically significant 
difference between both groups regarding 
mechanical ventilation time, ICU complications, 
and ICU stay period. There was no operative or 
early postoperative mortality in both groups. 
Similarly, in Pradhan's, Hoe's, and Nardi's studies, 
there was no statistically significant difference 
between both groups regarding the early 
postoperative morbidity and mortality [11 - 13]. 
 In our study, the immediate postoperative 
echo assessment of the grade of TR revealed that 
it was not significant in both groups despite the 
difference in the mean SPAP, which was 
significantly higher in the second group (66.31 ± 
3.4 versus 38.5 ± 6.4 mmHg). In our study, the rate 
of freedom of significant TR at the six-months was 
75.7%. Choi and colleagues reported 5.1% (9 
patients of 174) with the early progression of less 
than moderate TR to moderate or more severe TR 
[10]. In Smid's study, there was a significant 
reduction in the recurrence with reported 
freedom from significant FTR rate of 77.4% to 
100% (follow-up of between 3 and 79 months) 
[14]. A meta-analysis (of 2488 patients) by Kara 
and coworkers showed freedom from significant 
FTR in 77.1% to 100% of patients (n = 773) during 
follow-up of between 3 and 64.8 months [15]. 
 In the present study, there was a significant 
improvement of the NYHA functional class at six 
months postoperatively among both groups 
compared to the preoperative NYHA class. Despite 
the statistical difference between both groups, 
this result indicates that the left-sided lesion's 
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correction may improve the patient's functional 
class. Still, there was more improvement in 
successfully treating the FTR. Kim's study reported 
the same result regarding the improvement of his 
patients' functional class [1]. Also, Groves's study 
reported that patients with functional tricuspid 
regurgitation after mitral valve replacement have 
a reduced exercise capacity, maximal oxygen 
consumption, and anaerobic threshold compared 
with patients without tricuspid regurgitation, 
despite having good left ventricular and prosthetic 
valve function [10]. Despite the relatively high 
incidence of recurrent tricuspid regurgitation 
among our patients, they functionally tolerated 
moderate to severe regurgitation with minimal 
symptoms. Still, we couldn't accurately co-relate 
the functional class to right heart failure 
symptoms and degree of recurrent regurgitation. 
The logistic regression analysis revealed that 
the predictors of tricuspid repair failure in our case 
series were many factors. The most significant 
predictor was the persistence of severe 
pulmonary hypertension after surgery. 
Preoperative heart failure signs and the prolonged 
time between the indication of surgery and the 
operation were also considered predictors for 
DeVega repair failure. Other predictors included 
preoperative atrial fibrillation, severe pulmonary 
hypertension, and dilated RV. Predictors of failure 
of tricuspid repair in our case series were similar 
to other published studies. These predictive 
factors are not exclusive to the DeVega repair. 
Additional risk factors identified in other studies 
indicate that atrial fibrillation may cause 
recurrence, persistent pulmonary hypertension 
may have affected the suture repair and allowed 
the annulus to gradually dilate because of right 
ventricular systolic pressure did not significantly 
decrease during late follow-up [16,17]. 
Limitations 
This study is retrospective, with all the 
drawbacks of such studies. We studied only the 
early outcome, and long-term follow-up is 
recommended. 
Conclusion 
Tricuspid suture annuloplasty is associated 
with some degree of residual or recurrence 
tricuspid regurgitation. The study of predictors of 
failure could change our management plans to 
reach the best results for repair. 
Conflict of interest: Authors declare no conflict of 
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